Recursion Pharmaceuticals logo
Recursion Pharmaceuticals
RXRX | NASDAQ
Chart Builder DCF Calculator
$2.90
-$0.29 (-8.95%)
At close: Nov 16, 2026, 4:00 PM ET
$2.91
+$0.01 (+0.33%)
After-hours: Nov 16, 2026, 7:57 PM ET

Recursion Pharmaceuticals Company Profile

Company profile explained

Company Profile

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Key Executives

Name Position
Najat Khan CEO, President & Director
Ben R. Taylor Chief Financial Officer & President of Recursion UK
Benjamin Mabey Chief Technology Officer
Nathan Hatfield Chief Legal Officer & Corporate Secretary
David Hallett Chief Scientific Officer
Erica Fox Chief People and Impact Officer
Matthew Kinn Chief Business Officer
Ryan Kelly Chief Communications Officer
Sid Jain Senior Vice President of Clinical Development & Data Science
Vicki L. Goodman Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 15, 2026 424B5 Filing
Oct 15, 2026 8-K Current Report
Oct 15, 2026 424B5 Filing
Oct 07, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 21, 2026 8-K Current Report
Sep 16, 2026 4 Filing
Sep 10, 2026 4 Filing
View All SEC Filings ➞
Recursion Pharmaceuticals
Recursion Pharmaceuticals logo
Country United States
IPO Date Apr 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 600
CEO Najat Khan

Contact Details

41 South Rio Grande Street Salt Lake City, Utah 84101 United States

Stock Details

Ticker Symbol RXRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001601830
CUSIP Number 75629V104
ISIN Number US75629V1044
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.